Develops gene therapies for Rett syndrome.
Jun 2026Revenue $5.49M/yrExpenses $159M/yr
No trendCash runway ≈ 3.4 years from Jun 2026
Figures by year
When will Taysha Gene Therapies be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $5.49M and expenses $159M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $9.77M | $120M | −$110M |
| Dec 2024 | $8.33M | $99.8M | −$91.5M |
| Dec 2023 | $15.5M | $87.9M | −$72.4M |
| Dec 2022 | $2.50M | $165M | −$162M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.